Notes on R&D and EU market from May 16, 2013 event in Parliament on crisis is access to medicine in Europe

Below is a PDF from my presentation at the May 16, 2013 event in the EU Parliament on the Economic Crisis and Access to Medicines in Europe. While the main purpose of my talk was to discuss delinkage, I began with some data on the EU market and R&D outlays. I have pulled out one figure and two tables from the presentation and offer some comments here.

The figure below simulates the shape of the demand curve for Europe, if one assumes a constant elasticity of income for products, and insurance in each market.


Continue Reading

Uncategorized

Joint Letter to the 66th World Health Assembly: Follow-up of the report of the CEWG

Joint Letter to the 66th World Health Assembly: Follow-up of the report of the CEWG

20 May 2013

Distinguished Delegate,

We urge the World Health Organization (WHO) and its Member States to exercise leadership, ambition and innovative thinking in developing new paradigms to take forward the work of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) in reconciling the objectives of stimulating medical innovation and ensuring access for all.

Continue Reading

Uncategorized

Supreme Court Unanimously Finds Patent Exhaustion Does Not Apply to Seeds; Leaves Door Open on Other Self-Replicating Technology

On Monday, 13 May 2013, the Supreme Court of the United States unanimously held that patent exhaustion does not apply to second, third or nth generations of seeds. In an opinion authored by Justice Kagan, the court found that patent exhaustion does not apply to seeds because later generations constitute new copies of the invention. Continue Reading

Uncategorized

KEI Comments on US/EU Trade negotiations (TTIP), Docket No. USTR-2013-0019

A PDF version of our comments is available here.

People have until midnight May 10, 2013 to file comments, here:
http://www.regulations.gov/#!documentDetail;D=USTR-2013-0019-0001

This is the table of contents.

Comments on the Administration’s Intention to Enter Into Negotiations for the Transatlantic Trade and Investment Partnership (TTIP) Agreement
Response to Docket No. USTR-2013-0019

Introduction
Transparency
Continue Reading

Uncategorized

May 13 Brownbag lunch on WIPO treaty for blind negotiations

Note, we are adding some video clips from the meeting here:

  • May 13, 2013. KEI meeting on WIPO negotiations. http://www.youtube.com/playlist?list=PLLw9jWaZPEpzafm6_61VtLb6aW-nFaINa

  • On May 13, 2013, KEI will host a 12:30 to 2:30 brown bag lunch for a discussion of the WIPO Treaty for the Blind negotiations. It will be possible to attend in person, or follow the meeting on the telephone.

    Continue Reading

    Uncategorized

    Intellectual Property Owners Association (IPO) calls WIPO treaty for blind “dangerous precedent for other areas of IP Law”

    On April 15, 2013, the Intellectual Property Owners Association (IPO) sent a letter to Teresa Stanek Rea, the Acting Under Secretary of Commerce for Intellectual Property and the Director of the U.S. Patent and Trademark Office, setting out the IPO “concerns” about the proposed WIPO treaty for persons who are blind or visually impaired. (Copy here).

    Continue Reading

    Uncategorized

    Human Rights, Intellectual Property and Access to Medicines, notes from Yale workshop

    On April 26, 2013 I attended a half day meeting on “A Human Rights Approach to Intellectual Property and Access to Medicines” organized by the Yale Law School and the Yale School of Public Health. These are notes from my interventions on behalf of KEI.

    1. KEI does a lot of work on intellectual property rights that has impact on human rights. We do not always give prominence to human rights law or the language of human rights, although at times and in the right context, it can be important to do so.

    Continue Reading

    Uncategorized

    PhRMA press release on USTR Special 301, expresses disappointment over language for India, Canada

    Below is the PhRMA press release on the Special 301 Report.

    Key points in the PhRMA release:

    * PhRMA “dismayed that USTR did not grant an out-of-cycle review for India.” PhRMA claims that India decisions involving German owned Bayer and Swiss owned Novartis “disproportionately impacted U.S. biopharmaceutical companies.” (Perhaps PhRMA could have said, companies that have ownership claims on the US government).

    Continue Reading

    Uncategorized